Basel, Switzerland
Noema Pharma, founded in 2019, is a promising clinical-stage biotech company headquartered in Switzerland. The company’s mission is captured in its slogan: "A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions." They are on the frontier of developing groundbreaking therapies aimed at combating the significant challenges posed by orphan conditions of the brain and nervous system.
With a clear focus on biotechnology and pharmaceuticals, Noema Pharma is dedicated to understanding and addressing patient needs through its novel therapies. The company recently secured a substantial Fr.103.00M Series B investment on 07 March 2023. This funding round attracted a diverse group of investors including Polaris Partners, Sofinnova Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, and UPMC Enterprises, underscoring strong investor confidence in their innovative approach and potential for transformative impact in neurology.
